(c) 2024 PillSync.com

Rosuvastatin calcium 5 mg

1 INDICATIONS AND USAGE Rosuvastatin calcium tablets is indicated: To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: Reduce LDL-C in adults with primary hyperlipidemia. Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults. Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: primary dysbetalipoproteinemia. Hypertriglyceridemia. Rosuvastatin is an HMG Co-A reductase inhibitor (statin) indicated: (1) To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults. As an adjunct to diet to reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: primary dysbetalipoproteinemia. Hypertriglyceridemia.

tris pharma inc


4 years ago ROUND PINK CY 5 Rosuvastatin calcium 5 mg

ROUND PINK CY 5

4 years ago ROUND PINK CY 5 Rosuvastatin calcium 5 mg

CY 5 ROUND PINK

16 HOW SUPPLIED/STORAGE AND HANDLING

ROSUVASTATIN CALCIUM tablets are supplied as: Strength How Supplied NDC Tablet Description 5 mg bottles of 90 tablets bottles of 500 tablets NDC 27808-155-01 NDC 27808-155-03 pink, round, biconvex, coated tablets. debossed as ‘CY’ on one side and ‘5’ on other side 10 mg bottles of 90 tablets bottles of 500 tablets NDC 27808-156-01 NDC 27808-156-03 yellow, round, biconvex, coated tablets. debossed as ‘CY’ on one side, and ‘10’ on other side 20 mg bottles of 90 tablets bottles of 500 tablets NDC 27808-157-01 NDC 27808-157-03 yellow, round, biconvex, coated tablets. debossed as ‘CY’ on one side, and ‘20’ on other side 40 mg bottles of 30 tablets bottles of 500 tablets NDC 27808-158-01 NDC 27808-158-03 pink, round, biconvex, coated tablet. debossed as ‘CY’ on one side, and ‘40’ on other side Storage Store at controlled room temperature, 20ºC to 25ºC (68ºF to 77ºF); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from moisture.


More pills like ROUND CY 5

Related Pills

rosuvastatin 10 mg

Tris Pharma Inc

rosuvastatin 20 mg

tris pharma inc

Rosuvastatin calcium 5 mg

tris pharma inc

rosuvastatin 20 mg

tris pharma inc

Rosuvastatin calcium 5 mg

tris pharma inc

Rosuvastatin calcium 40 mg

Tris Pharma Inc

rosuvastatin 10 mg

tris pharma inc












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site